Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival

Aaron Struck, Thomas Howard, Elena G. Chiorean, Jeffrey M. Clarke, Robert Riffenburgh, Higinia R. Cardenes

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Duodenal adenocarcinoma (DA) is rare, but potentially curable. Prospective data on treatment outcomes is scarce and large retrospective studies show conflicting results on the impact of radical resection, node-status, and adjuvant therapy. Methods: In the past 17 years, 30 patients presented with resectable DA. Data on the aforementioned variables were acquired then analyzed for impact on recurrence and survival. Results: Overall-survival rates at 1, 2, and 3 years were 70.0%, 53.3%, and 33.3% respectively. Recurrence-free survival rates at 1, 2, and 3 years were 53.3%, 30.0%, and 26.7%. Overall-survival rates for patients with node-positive disease at 1, 2, and 3 years were 68.8%, 43.8%, 12.5%, and for node-negative 70%, 60%, 60%. Recurrence-free survival in node-positive disease at 1, 2, 3 years was 50%, 12.5%, 12.5%, and for node negative 50%, 50%, and 40%. Median survival from diagnosis was 27.5 months (0.5-226.7 months). Significant predictors of recurrence and survival were nodal-status and AJCC stage (P < 0.001). Adjuvant therapy, surgical-type, pathological tumor-stage, and surgical margins were not significant. Conclusion: Nodal-status and overall pathological-stage significantly affect the prognosis for patients withDA, while resection-status and adjuvant therapy may not. The role of adjuvant therapy requires prospective trials for elucidation.

Original languageEnglish
Pages (from-to)144-148
Number of pages5
JournalJournal of Surgical Oncology
Volume100
Issue number2
DOIs
StatePublished - Aug 1 2009

Fingerprint

Adenocarcinoma
Recurrence
Survival
Survival Rate
Therapeutics
Retrospective Studies
Neoplasms

Keywords

  • Adjuvant therapy
  • Nodal status
  • Radical resection
  • Small bowel malignancy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Struck, A., Howard, T., Chiorean, E. G., Clarke, J. M., Riffenburgh, R., & Cardenes, H. R. (2009). Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival. Journal of Surgical Oncology, 100(2), 144-148. https://doi.org/10.1002/jso.21319

Non-ampullary duodenal adenocarcinoma : Factors important for relapse and survival. / Struck, Aaron; Howard, Thomas; Chiorean, Elena G.; Clarke, Jeffrey M.; Riffenburgh, Robert; Cardenes, Higinia R.

In: Journal of Surgical Oncology, Vol. 100, No. 2, 01.08.2009, p. 144-148.

Research output: Contribution to journalArticle

Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R & Cardenes, HR 2009, 'Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival', Journal of Surgical Oncology, vol. 100, no. 2, pp. 144-148. https://doi.org/10.1002/jso.21319
Struck, Aaron ; Howard, Thomas ; Chiorean, Elena G. ; Clarke, Jeffrey M. ; Riffenburgh, Robert ; Cardenes, Higinia R. / Non-ampullary duodenal adenocarcinoma : Factors important for relapse and survival. In: Journal of Surgical Oncology. 2009 ; Vol. 100, No. 2. pp. 144-148.
@article{d3297b0caa6542dcbecc59379d43ca66,
title = "Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival",
abstract = "Background: Duodenal adenocarcinoma (DA) is rare, but potentially curable. Prospective data on treatment outcomes is scarce and large retrospective studies show conflicting results on the impact of radical resection, node-status, and adjuvant therapy. Methods: In the past 17 years, 30 patients presented with resectable DA. Data on the aforementioned variables were acquired then analyzed for impact on recurrence and survival. Results: Overall-survival rates at 1, 2, and 3 years were 70.0{\%}, 53.3{\%}, and 33.3{\%} respectively. Recurrence-free survival rates at 1, 2, and 3 years were 53.3{\%}, 30.0{\%}, and 26.7{\%}. Overall-survival rates for patients with node-positive disease at 1, 2, and 3 years were 68.8{\%}, 43.8{\%}, 12.5{\%}, and for node-negative 70{\%}, 60{\%}, 60{\%}. Recurrence-free survival in node-positive disease at 1, 2, 3 years was 50{\%}, 12.5{\%}, 12.5{\%}, and for node negative 50{\%}, 50{\%}, and 40{\%}. Median survival from diagnosis was 27.5 months (0.5-226.7 months). Significant predictors of recurrence and survival were nodal-status and AJCC stage (P < 0.001). Adjuvant therapy, surgical-type, pathological tumor-stage, and surgical margins were not significant. Conclusion: Nodal-status and overall pathological-stage significantly affect the prognosis for patients withDA, while resection-status and adjuvant therapy may not. The role of adjuvant therapy requires prospective trials for elucidation.",
keywords = "Adjuvant therapy, Nodal status, Radical resection, Small bowel malignancy",
author = "Aaron Struck and Thomas Howard and Chiorean, {Elena G.} and Clarke, {Jeffrey M.} and Robert Riffenburgh and Cardenes, {Higinia R.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1002/jso.21319",
language = "English",
volume = "100",
pages = "144--148",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Non-ampullary duodenal adenocarcinoma

T2 - Factors important for relapse and survival

AU - Struck, Aaron

AU - Howard, Thomas

AU - Chiorean, Elena G.

AU - Clarke, Jeffrey M.

AU - Riffenburgh, Robert

AU - Cardenes, Higinia R.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Duodenal adenocarcinoma (DA) is rare, but potentially curable. Prospective data on treatment outcomes is scarce and large retrospective studies show conflicting results on the impact of radical resection, node-status, and adjuvant therapy. Methods: In the past 17 years, 30 patients presented with resectable DA. Data on the aforementioned variables were acquired then analyzed for impact on recurrence and survival. Results: Overall-survival rates at 1, 2, and 3 years were 70.0%, 53.3%, and 33.3% respectively. Recurrence-free survival rates at 1, 2, and 3 years were 53.3%, 30.0%, and 26.7%. Overall-survival rates for patients with node-positive disease at 1, 2, and 3 years were 68.8%, 43.8%, 12.5%, and for node-negative 70%, 60%, 60%. Recurrence-free survival in node-positive disease at 1, 2, 3 years was 50%, 12.5%, 12.5%, and for node negative 50%, 50%, and 40%. Median survival from diagnosis was 27.5 months (0.5-226.7 months). Significant predictors of recurrence and survival were nodal-status and AJCC stage (P < 0.001). Adjuvant therapy, surgical-type, pathological tumor-stage, and surgical margins were not significant. Conclusion: Nodal-status and overall pathological-stage significantly affect the prognosis for patients withDA, while resection-status and adjuvant therapy may not. The role of adjuvant therapy requires prospective trials for elucidation.

AB - Background: Duodenal adenocarcinoma (DA) is rare, but potentially curable. Prospective data on treatment outcomes is scarce and large retrospective studies show conflicting results on the impact of radical resection, node-status, and adjuvant therapy. Methods: In the past 17 years, 30 patients presented with resectable DA. Data on the aforementioned variables were acquired then analyzed for impact on recurrence and survival. Results: Overall-survival rates at 1, 2, and 3 years were 70.0%, 53.3%, and 33.3% respectively. Recurrence-free survival rates at 1, 2, and 3 years were 53.3%, 30.0%, and 26.7%. Overall-survival rates for patients with node-positive disease at 1, 2, and 3 years were 68.8%, 43.8%, 12.5%, and for node-negative 70%, 60%, 60%. Recurrence-free survival in node-positive disease at 1, 2, 3 years was 50%, 12.5%, 12.5%, and for node negative 50%, 50%, and 40%. Median survival from diagnosis was 27.5 months (0.5-226.7 months). Significant predictors of recurrence and survival were nodal-status and AJCC stage (P < 0.001). Adjuvant therapy, surgical-type, pathological tumor-stage, and surgical margins were not significant. Conclusion: Nodal-status and overall pathological-stage significantly affect the prognosis for patients withDA, while resection-status and adjuvant therapy may not. The role of adjuvant therapy requires prospective trials for elucidation.

KW - Adjuvant therapy

KW - Nodal status

KW - Radical resection

KW - Small bowel malignancy

UR - http://www.scopus.com/inward/record.url?scp=67749110202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749110202&partnerID=8YFLogxK

U2 - 10.1002/jso.21319

DO - 10.1002/jso.21319

M3 - Article

C2 - 19544358

AN - SCOPUS:67749110202

VL - 100

SP - 144

EP - 148

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -